Chiasma Inc
NASDAQ:CHMA (8/5/2021, 7:18:03 PM)
After market: 3.78 +0.02 (+0.53%)3.76
-0.24 (-6%)
Chiasma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of oral forms of therapies that are available by injection. The company is headquartered in Needham, Massachusetts and currently employs 85 full-time employees. The company went IPO on 2015-07-16. The firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The firm has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The firm is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The firm's TPE technology enhances the absorption through the intestinal wall of drugs. The firm also focuses on developing CH2 for Orphan indication.
Chiasma Inc
140 Kendrick Street, Building C East
Needham MASSACHUSETTS 02494
P: 16179285300.0
CEO: Raj Kannan
Employees: 85
Website: http://www.chiasmapharma.com/
Here you can normally see the latest stock twits on CHMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: